Testing a medication reminder app for lung and heart conditions
Part of Blood & lymphatic, Heart & circulation, Immune system & allergy, Lungs & breathing clinical trials.
This study compares a smartphone app called FORTISKAP™ that reminds you to take your medications versus standard care. The trial includes people with interstitial lung disease (a scarring condition of the lungs), sarcoidosis (an inflammatory condition), or pulmonary hypertension (high blood pressure in the lungs), and aims to see if the app helps people take their medications more reliably.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 21 years or older
- You have been diagnosed with interstitial lung disease (including sarcoidosis) and/or pulmonary hypertension
- You currently take your medications on your own without someone else giving them to you
- You are already taking at least one oral medication for your lung or heart condition, or have insurance approval to start one soon
- You have a recent breathing test (6-minute walk test) scheduled or completed in the last 30 days
- You have a smartphone with a working internet connection and can use the FORTISKAP™ app, and you speak English
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a motivational interviewing program can help people with idiopathic pulmonary fibrosis improve their self-care skills over time. You will be assigned to either the program group or a usual care group, and your self-care will be tracked for 18 months.
This study tests whether a home-based exercise program, guided by a smartphone app, can improve your daily life and heart function if you have pulmonary hypertension. You will use a wearable device to track your activity and receive remote support from a medical team.
This trial tests whether a smartphone app can help people with GERD or erosive esophagitis stick to their medicine better than just using the pharmacy records. You might join if you already take a daily proton pump inhibitor (like omeprazole or pantoprazole) and want to use an app for 90 days.
This trial tests whether a digital self-management program (using a smartphone or tablet) helps people with fibrotic interstitial lung disease better manage their symptoms and quality of life. If you have this lung condition and can use a mobile device, this study could offer you extra support at home.
This study tests if a smartphone app can help people with pulmonary arterial hypertension (PAH) stick to their inhaled iloprost treatment. It is for adults already on this treatment at a specific clinic in Brazil.
This trial tests whether people with lung disease caused by a rheumatic condition can safely manage their care at home using a smartphone or tablet. It aims to see if home monitoring is as effective as in-person visits for keeping your lungs healthy.
Hear when a new Pulmonary Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.